Clomiphene: common myths examined

Many beliefs have formed around clomiphene — from "it lowers estrogen" to "guaranteed to restore hormones after a course." The editors analyzed the most common claims and checked them against the official instructions, clinical guidelines and scientific data.

Where do the myths about clomiphene come from

Clomiphene is one of the oldest drugs in its group: it has been used in reproductive medicine since the 1960s. During this time, many beliefs were formed around it, especially in the sports environment, where the drug became part of informal "recovery" schemes after anabolic steroids. A large part of these ideas are transmitted from forums and chat rooms, not from the medical literature.

The reason for the survival of myths is the combination of real facts with excessive generalizations. Clomiphene is really able to increase testosterone in some men, is really used off-label by urologists, is really relatively inexpensive. But from these facts they draw conclusions that are not supported by the data.

The editors have collected the most common statements and compared them with what is known from official instructions, clinical guidelines and research. The goal is neither to "demonize" nor to promote the drug - only to distinguish between evidence and speculation.

We remind you that clomiphene is a prescription drug. None of the following explanations should be taken as instructions for use.

Myths about action and effectiveness

Myth 1: "Clomiphene lowers estrogen"

This is probably the most common misunderstanding. Clomiphene is not an aromatase inhibitor, and it does not reduce the formation of estrogens. The drug blocks estrogen receptors in the hypothalamus, as a result of which the production of LH and testosterone increases.

Because testosterone is partially converted to estradiol, blood estradiol levels usually increase, not decrease, in men taking clomiphene. That is why estradiol control is included in laboratory monitoring, and gynecomastia occurs among side effects.

Myth 2: "Clomiphene works the same for everyone"

Response to clomiphene depends on the cause of low testosterone. The drug can only work when the pituitary gland and testicles are able to respond to stimulation. With primary hypogonadism, when the testicles themselves are affected, and LH is already high, there is no reason to expect an effect.

Even among men with secondary hypogonadism, the response varies: in retrospective studies, some patients showed a significant increase in testosterone, others - moderate, and in some, the improvement of symptoms did not correspond to the dynamics of the tests.

Myth 3: "The higher the dose, the better the result"

For clomiphene, as for many drugs, the dose-effect relationship is not linear. Increasing the dose does not guarantee a proportional increase in testosterone, but increases the likelihood of adverse reactions, primarily an increase in estradiol, psychoemotional and visual disturbances.

The instructions for women provide for a careful dose increase only under medical supervision and with a limit on the number of courses. Approved product labeling does not provide a male treatment regimen, so independent experiments with doses are devoid of any basis.

Myths about safety

Myth 4: "Clomiphene has virtually no side effects"

Clomiphene is generally well tolerated, but “well” does not mean “free of effects”. The official instructions describe hot flashes, abdominal discomfort, ovarian enlargement in women, headache, nausea, and mood swings. The most serious "red flag" is visual disturbances, in which treatment should be stopped and prompt ophthalmological assessment obtained.

In men, effects related to increased estradiol are added, as well as complaints of irritability and impaired sleep. Some researchers associate them with the accumulation of zuclomiphene, an isomer with a long elimination period.

Myth 5: "Since clomiphene has been sold for a long time, it can be taken for years without control"

Long-term experience of use refers mainly to short courses of ovulation induction. Retrospective studies of long-term use in men, in particular the work of Krzastek et al. (2019), showed an acceptable safety profile, but only under the condition of regular medical monitoring and tests.

Without control, it is impossible to notice the growth of estradiol, changes in the lipid profile or other deviations in time. So "long on the market" does not equal "safe in any mode".

Myths about steroid recovery

Myth 6: "Clomiphene is guaranteed to restore the hormonal system after a course"

There are few high-quality scientific data on clomiphene specifically after AAS. A review by Rahnema et al (2014) describes SERMs as one possible approach, but highlights the limitations of the evidence. There are virtually no controlled studies proving that clomiphene shortens recovery time compared to spontaneous recovery.

Duration of suppression, age, total androgen exposure, and baseline testicular status influence prognosis significantly more than any single drug. In some men, axis function is restored only partially or very slowly.

Myth 7: "Clomiphene can be replaced with "natural boosters""

Most herbal “testosterone boosters” do not have conclusive evidence to increase testosterone in healthy men. At the same time, some products of this category were found to be falsified during inspections - with undeclared pharmacological substances.

Comparing these products to clomiphene is incorrect in both directions: they are not a "soft" substitute for a prescription drug, and clomiphene itself is not a dietary supplement.

Myths about sports and doping

Myth 8: "Clomiphene is not doping, because it is not anabolic"

The WADA Prohibited List includes not only anabolic agents. Clomiphene belongs to the hormonal and metabolic modulators section, in the anti-estrogenic substances division, and is prohibited both in and out of competition for men and women.

The reason is that the drug changes the levels of endogenous hormones and can be used to mask the effects of using AAS. Therefore, a positive test for clomiphene is a violation of anti-doping rules, unless the applicable therapeutic-use rules have been met.

Myth 9: "Clomiphene alone increases strength and mass"

Clomiphene increases testosterone within the physiological range in men with secondary hypogonadism. This can improve well-being and symptoms of deficiency, but does not reliably produce the supraphysiological androgen exposure, which are associated with a pronounced anabolic effect.

For a healthy person with normal testosterone, there is no reason to expect a noticeable increase in muscle mass from clomiphene, and the risks of side effects and disqualification remain.

Editorial conclusions

Most of the myths about clomiphene arise from confusing the mechanism of action with the clinical outcome. The drug does not reduce estrogen, but blocks its receptors; does not affect everyone equally; is not safe "in any mode"; does not guarantee recovery after AAS.

Clomiphene has a well-founded place in medicine — from ovulation induction to off-label treatment of secondary hypogonadism in men planning parenthood. But this place is determined by diagnosis, tests and medical supervision.

For athletes, the key fact is simple: clomiphene is prohibited at all times by WADA, and its use without therapeutic approval is a violation of the rules.

For a complete picture, we recommend reading our articles on Clomiphene side effects, contraindications and interactions, and enclomiphene and how it differs from clomiphene.

References

1. Clomid (clomiphene citrate tablets USP). Prescribing information. U.S. Food and Drug Administration.
2. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
3. Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573–578.
4. Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. J Urol. 2019;202(5):1029–1035.
5. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate: an assessment of androgen levels and symptoms. J Urol. 2014;192(3):875–879.
6. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423–432.
7. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; актуальна редакція.